Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice

References

• Ferrari S, Serra M. An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother 2015; 16(18):2727-36; PMID:26512909; http://dx.doi.org/10.1517/14656566.2015.1102226
   PubMed Web of Science ®Google Scholar
• Wang Z, Li B, Ren Y, Ye Z. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities. Front Immunol 2016; 7:353; PMID:27683579; http://dx.doi.org/10.3389/fimmu.2016.00353
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33(15):1688-96; PMID:25800760; http://dx.doi.org/10.1200/JCO.2014.58.0225
   PubMed Web of Science ®Google Scholar
• Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012; 72(1):271-81; PMID:22075555; http://dx.doi.org/10.1158/0008-5472.CAN-11-2778
   PubMed Web of Science ®Google Scholar
• Li B, Zhu X, Sun L, Yuan L, Zhang J, Li H, Ye Z. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma. Oncotarget 2014; 5(21):10791-802; PMID:25301731; http://dx.doi.org/10.18632/oncotarget.2505
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang Y. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014; 2(7):690-8; PMID:24866169; http://dx.doi.org/10.1158/2326-6066.CIR-13-0224
   PubMed Web of Science ®Google Scholar
• Salvatore V, Focaroli S, Teti G, Mazzotti A, Falconi M. Changes in the gene expression of co-cultured human fibroblast cells and osteosarcoma cells: the role of microenvironment. Oncotarget 2015; 6(30):28988-98; PMID:26418748; http://dx.doi.org/10.18632/oncotarget.4902
   PubMed Web of Science ®Google Scholar
• Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 2015; 3:21; PMID:25992292; http://dx.doi.org/10.1186/s40425-015-0067-z
   PubMed Web of Science ®Google Scholar
• Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 2003; 24(6):302-6; PMID:12810105; http://dx.doi.org/10.1016/S1471-4906(03)00132-7
   PubMed Web of Science ®Google Scholar
• Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005; 201(8):1257-68; PMID:15824085; http://dx.doi.org/10.1084/jem.20042028
   PubMed Web of Science ®Google Scholar
• Patil MD, Bhaumik J, Babykutty S, Banerjee UC, Fukumura D. Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene 2016; 35(38):4957-72; PMID:27109103; http://dx.doi.org/10.1038/onc.2016.37
   PubMed Web of Science ®Google Scholar
• Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015; 162(6):1229-41; PMID:26321679; http://dx.doi.org/10.1016/j.cell.2015.08.016
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109(4):1568-73; PMID:17023580; http://dx.doi.org/10.1182/blood-2006-06-031856
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 2002; 277(24):21123-9; PMID:11950832; http://dx.doi.org/10.1074/jbc.M110675200
   PubMed Web of Science ®Google Scholar
• Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, Kogadeeva M, Picotti P, Meissner F, Mann M, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 2016; 167(3):829-42; PMID:27745970; http://dx.doi.org/10.1016/j.cell.2016.09.031
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang Q, Du Y, Liu F, Zhang Y, Feng Y, Jin F. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice. Int Immunopharmacol 2016; 35:7-14; PMID:27003114; http://dx.doi.org/10.1016/j.intimp.2016.03.002
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol 2016; 13(6):370-83; PMID:27000958; http://dx.doi.org/10.1038/nrclinonc.2016.36
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 2015; 21(5):1019-27; PMID:25538264; http://dx.doi.org/10.1158/1078-0432.CCR-14-2708
   PubMed Web of Science ®Google Scholar
• Lettieri CK, Appel N, Labban N, Lussier DM, Blattman JN, Hingorani P. Progress and opportunities for immune therapeutics in osteosarcoma. Immunotherapy 2016; 8(10):1233-44; PMID:27605071; http://dx.doi.org/10.2217/imt-2016-0048
   PubMed Web of Science ®Google Scholar
• Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, Tsui YC, Cui G, Micevic G, Perales JC, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015; 162(6):1217-28; PMID:26321681; http://dx.doi.org/10.1016/j.cell.2015.08.012
   PubMed Web of Science ®Google Scholar
• Dufait I, Schwarze JK, Liechtenstein T, Leonard W, Jiang H, Escors D, De Ridder M, Breckpot K. Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. Oncotarget 2015; 6(14):12369-82; PMID:25869209; http://dx.doi.org/10.18632/oncotarget.3682
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8(328):324r-8r; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
   Web of Science ®Google Scholar
• Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125(9):3384-91; PMID:26325035; http://dx.doi.org/10.1172/JCI80011
   PubMed Web of Science ®Google Scholar